O	0	3	Can
O	4	13	treatment
O	14	18	with
B-intervention	19	28	Cocculine
O	29	36	improve
O	37	40	the
O	41	48	control
O	49	51	of
B-condition	52	64	chemotherapy
I-condition	64	65	-
I-condition	65	72	induced
I-condition	73	79	emesis
O	80	82	in
O	83	88	early
O	89	95	breast
O	96	102	cancer
O	103	111	patients
O	111	112	?

O	113	114	A
O	115	125	randomized
O	125	126	,
O	127	132	multi
O	132	133	-
O	133	141	centered
O	141	142	,
O	143	149	double
O	149	150	-
O	150	155	blind
O	155	156	,
O	157	164	placebo
O	164	165	-
O	165	175	controlled
O	176	181	Phase
O	182	185	III
O	186	191	trial
O	191	192	.

O	193	205	Chemotherapy
O	206	213	induced
O	214	220	nausea
O	221	224	and
O	225	233	vomiting
O	234	235	(
O	235	239	CINV
O	239	240	)
O	241	248	remains
O	249	250	a
O	251	256	major
O	257	264	problem
O	265	269	that
O	270	279	seriously
O	280	287	impairs
O	288	291	the
O	292	299	quality
O	300	302	of
O	303	307	life
O	308	309	(
O	309	312	QoL
O	312	313	)
O	314	316	in
O	317	323	cancer
O	324	332	patients
O	333	342	receiving
O	343	355	chemotherapy
O	356	364	regimens
O	364	365	.

O	366	379	Complementary
O	380	389	medicines
O	389	390	,
O	391	400	including
O	401	411	homeopathy
O	411	412	,
O	413	416	are
O	417	421	used
O	422	424	by
O	425	429	many
O	430	438	patients
O	439	443	with
O	444	450	cancer
O	450	451	,
O	452	459	usually
O	460	469	alongside
O	470	474	with
O	475	487	conventional
O	488	497	treatment
O	497	498	.

O	499	500	A
O	501	511	randomized
O	511	512	,
O	513	520	placebo
O	520	521	-
O	521	531	controlled
O	532	537	Phase
O	538	541	III
O	542	547	study
O	548	551	was
O	552	561	conducted
O	562	564	to
O	565	573	evaluate
O	574	577	the
O	578	586	efficacy
O	587	589	of
O	590	591	a
O	592	599	complex
O	600	611	homeopathic
O	612	620	medicine
O	620	621	,
O	622	631	Cocculine
O	631	632	,
O	633	635	in
O	636	639	the
O	640	647	control
O	648	650	of
O	651	655	CINV
O	656	658	in
O	659	662	non
O	662	663	-
O	663	673	metastatic
O	674	680	breast
O	681	687	cancer
O	688	696	patients
O	697	704	treated
O	705	707	by
O	708	716	standard
O	717	729	chemotherapy
O	730	738	regimens
O	738	739	.

B-eligibility	740	752	Chemotherapy
I-eligibility	752	753	-
I-eligibility	753	755	na
I-eligibility	755	756	ï
I-eligibility	756	758	ve
I-eligibility	759	767	patients
I-eligibility	768	772	with
I-eligibility	773	776	non
I-eligibility	776	777	-
I-eligibility	777	787	metastatic
I-eligibility	788	794	breast
I-eligibility	795	801	cancer
O	802	811	scheduled
O	812	814	to
O	815	822	receive
O	823	824	6
O	825	831	cycles
O	832	834	of
O	835	847	chemotherapy
O	848	857	including
O	858	860	at
O	861	866	least
O	867	872	three
O	873	880	initial
O	881	887	cycles
O	888	890	of
O	891	894	FAC
O	895	897	50
O	897	898	,
O	899	902	FEC
O	903	906	100
O	907	909	or
O	910	913	TAC
O	914	918	were
O	919	929	randomized
O	930	932	to
O	933	940	receive
O	941	949	standard
O	950	954	anti
O	954	955	-
O	955	961	emetic
O	962	971	treatment
O	972	976	plus
O	977	983	either
O	984	985	a
O	986	993	complex
O	994	1005	homeopathic
O	1006	1012	remedy
O	1013	1014	(
O	1014	1023	Cocculine
O	1023	1024	,
O	1025	1035	registered
O	1036	1038	in
O	1039	1045	France
O	1046	1049	for
O	1050	1059	treatment
O	1060	1062	of
O	1063	1069	nausea
O	1070	1073	and
O	1074	1080	travel
O	1081	1089	sickness
O	1089	1090	)
O	1091	1093	or
O	1094	1097	the
O	1098	1106	matching
O	1107	1114	placebo
O	1115	1116	(
O	1116	1127	NCT00409071
O	1128	1142	clinicaltrials
O	1142	1143	.
O	1143	1146	gov
O	1146	1147	)
O	1147	1148	.

O	1149	1152	The
O	1153	1160	primary
O	1161	1169	endpoint
O	1170	1173	was
B-outcome-Measure	1174	1180	nausea
I-outcome-Measure	1181	1186	score
O	1187	1195	measured
O	1196	1201	after
O	1202	1205	the
O	1206	1209	1st
O	1210	1222	chemotherapy
O	1223	1229	course
O	1230	1235	using
O	1236	1239	the
O	1240	1244	FLIE
O	1245	1258	questionnaire
O	1259	1260	(
O	1260	1270	Functional
O	1271	1277	Living
O	1278	1283	Index
O	1284	1287	for
O	1288	1294	Emesis
O	1294	1295	)
O	1296	1300	with
O	1301	1302	5
O	1302	1303	-
O	1303	1306	day
O	1307	1313	recall
O	1313	1314	.

O	1315	1324	Secondary
O	1325	1334	endpoints
O	1335	1339	were
O	1339	1340	:
B-outcome-Measure	1341	1349	vomiting
O	1350	1358	measured
O	1359	1361	by
O	1362	1365	the
O	1366	1370	FLIE
O	1371	1376	score
O	1376	1377	,
B-outcome-Measure	1378	1384	nausea
I-outcome-Measure	1385	1388	and
I-outcome-Measure	1389	1397	vomiting
O	1398	1406	measured
O	1407	1409	by
O	1410	1417	patient
O	1418	1422	self
O	1422	1423	-
O	1423	1433	evaluation
O	1434	1435	(
O	1435	1438	EVA
O	1438	1439	)
O	1440	1443	and
O	1444	1456	investigator
O	1457	1466	recording
O	1467	1468	(
O	1468	1471	NCI
O	1471	1472	-
O	1472	1475	CTC
O	1476	1478	AE
O	1479	1481	V3
O	1481	1482	.
O	1482	1483	0
O	1483	1484	)
O	1485	1488	and
B-outcome-Measure	1489	1498	treatment
I-outcome-Measure	1499	1509	compliance
O	1509	1510	.

O	1511	1515	From
O	1516	1525	September
O	1526	1530	2005
O	1531	1533	to
O	1534	1541	January
O	1542	1546	2008
O	1546	1547	,
B-total-participants	1548	1551	431
O	1552	1560	patients
O	1561	1565	were
O	1566	1576	randomized
O	1576	1577	:
B-intervention-participants	1578	1581	214
O	1582	1584	to
O	1585	1594	Cocculine
O	1595	1596	(
O	1596	1597	C
O	1597	1598	)
O	1599	1602	and
B-control-participants	1603	1606	217
O	1607	1609	to
B-control	1610	1617	placebo
I-control	1618	1619	(
I-control	1619	1620	P
I-control	1620	1621	)
O	1621	1622	.

O	1623	1630	Patient
O	1631	1646	characteristics
O	1647	1651	were
O	1652	1656	well
O	1656	1657	-
O	1657	1665	balanced
O	1666	1673	between
O	1674	1677	the
O	1678	1679	2
O	1680	1684	arms
O	1684	1685	.

O	1686	1693	Overall
O	1693	1694	,
B-outcome	1695	1705	compliance
O	1706	1708	to
O	1709	1714	study
O	1715	1725	treatments
O	1726	1729	was
O	1730	1739	excellent
O	1740	1743	and
O	1744	1751	similar
O	1752	1759	between
O	1760	1763	the
O	1764	1765	2
O	1766	1770	arms
O	1770	1771	.

O	1772	1773	A
O	1774	1779	total
O	1780	1782	of
O	1783	1786	205
O	1787	1795	patients
O	1796	1797	(
O	1797	1799	50
O	1799	1800	.
O	1800	1801	9
O	1801	1802	%
O	1802	1803	;
B-cv-bin-abs	1804	1807	103
O	1808	1816	patients
O	1817	1819	in
O	1820	1823	the
O	1824	1831	placebo
O	1832	1835	and
B-iv-bin-abs	1836	1839	102
O	1840	1842	in
O	1843	1846	the
O	1847	1857	homeopathy
O	1858	1862	arms
O	1862	1863	)
O	1864	1867	had
B-outcome	1868	1874	nausea
I-outcome	1875	1879	FLIE
I-outcome	1880	1886	scores
I-outcome	1887	1888	>
I-outcome	1889	1890	6
O	1891	1901	indicative
O	1902	1904	of
O	1905	1907	no
O	1908	1914	impact
O	1915	1917	of
O	1918	1924	nausea
O	1925	1927	on
O	1928	1935	quality
O	1936	1938	of
O	1939	1943	life
O	1944	1950	during
O	1951	1954	the
O	1955	1958	1st
O	1959	1971	chemotherapy
O	1972	1978	course
O	1978	1979	.

O	1980	1985	There
O	1986	1989	was
O	1990	1992	no
O	1993	2003	difference
O	2004	2011	between
O	2012	2015	the
O	2016	2017	2
O	2018	2022	arms
O	2023	2027	when
O	2028	2035	primary
O	2036	2044	endpoint
O	2045	2053	analysis
O	2054	2057	was
O	2058	2067	performed
O	2068	2070	by
O	2071	2083	chemotherapy
O	2084	2091	stratum
O	2091	2092	;
O	2093	2095	or
O	2096	2098	in
O	2099	2102	the
O	2103	2111	subgroup
O	2112	2114	of
O	2115	2123	patients
O	2124	2128	with
O	2129	2143	susceptibility
O	2144	2146	to
O	2147	2153	nausea
O	2154	2157	and
O	2158	2166	vomiting
O	2167	2173	before
O	2174	2183	inclusion
O	2183	2184	.

O	2185	2187	In
O	2188	2196	addition
O	2196	2197	,
B-outcome	2198	2204	nausea
O	2204	2205	,
B-outcome	2206	2214	vomiting
O	2215	2218	and
B-outcome	2219	2225	global
I-outcome	2226	2232	emesis
I-outcome	2233	2237	FLIE
I-outcome	2238	2244	scores
O	2245	2249	were
O	2250	2253	not
O	2254	2267	statistically
O	2268	2277	different
O	2278	2280	at
O	2281	2284	any
O	2285	2289	time
O	2290	2297	between
O	2298	2301	the
O	2302	2305	two
O	2306	2311	study
O	2312	2316	arms
O	2316	2317	.

O	2318	2321	The
O	2322	2333	frequencies
O	2334	2336	of
B-outcome	2337	2343	severe
I-outcome	2344	2345	(
I-outcome	2345	2350	Grade
I-outcome	2351	2352	≥
I-outcome	2353	2354	2
I-outcome	2354	2355	)
I-outcome	2356	2362	nausea
O	2363	2366	and
B-outcome	2367	2375	vomiting
O	2376	2380	were
O	2381	2384	low
O	2385	2387	in
O	2388	2391	our
O	2392	2397	study
O	2398	2399	(
B-outcome	2399	2405	nausea
O	2405	2406	:
O	2407	2408	P
O	2408	2409	:
B-cv-bin-percent	2410	2412	17
I-cv-bin-percent	2412	2413	.
I-cv-bin-percent	2413	2414	6
I-cv-bin-percent	2414	2415	%
O	2416	2418	vs
O	2419	2420	C
O	2420	2421	:
B-iv-bin-percent	2422	2424	15
I-iv-bin-percent	2424	2425	.
I-iv-bin-percent	2425	2426	7
I-iv-bin-percent	2426	2427	%
O	2427	2428	,
O	2429	2430	p
O	2430	2431	=
O	2431	2432	0
O	2432	2433	.
O	2433	2435	62
O	2435	2436	;
B-outcome	2437	2445	vomiting
O	2445	2446	:
O	2447	2448	P
O	2448	2449	:
B-cv-bin-percent	2450	2452	10
I-cv-bin-percent	2452	2453	.
I-cv-bin-percent	2453	2454	8
I-cv-bin-percent	2454	2455	%
O	2456	2458	vs
O	2459	2460	C
O	2460	2461	:
B-iv-bin-percent	2462	2464	12
I-iv-bin-percent	2464	2465	.
I-iv-bin-percent	2465	2466	0
I-iv-bin-percent	2466	2467	%
O	2467	2468	,
O	2469	2470	p
O	2470	2471	=
O	2471	2472	0
O	2472	2473	.
O	2473	2475	72
O	2476	2482	during
O	2483	2486	the
O	2487	2492	first
O	2493	2499	course
O	2499	2500	)
O	2500	2501	.

O	2502	2506	This
O	2507	2513	double
O	2513	2514	-
O	2514	2521	blinded
O	2521	2522	,
O	2523	2530	placebo
O	2530	2531	-
O	2531	2541	controlled
O	2541	2542	,
O	2543	2553	randomised
O	2554	2559	Phase
O	2560	2563	III
O	2564	2569	study
O	2570	2576	showed
O	2577	2581	that
O	2582	2588	adding
O	2589	2590	a
O	2591	2598	complex
O	2599	2610	homeopathic
O	2611	2619	medicine
O	2620	2621	(
O	2621	2630	Cocculine
O	2630	2631	)
O	2632	2634	to
O	2635	2643	standard
O	2644	2648	anti
O	2648	2649	-
O	2649	2655	emetic
O	2656	2667	prophylaxis
O	2668	2672	does
O	2673	2676	not
O	2677	2684	improve
O	2685	2688	the
O	2689	2696	control
O	2697	2699	of
O	2700	2704	CINV
O	2705	2707	in
O	2708	2713	early
O	2714	2720	breast
O	2721	2727	cancer
O	2728	2736	patients
O	2736	2737	.
